Tirzepatide.
S💡 Explain this simply
Tirzepatide is an approved drug in the glp-1 & incretin receptor agonists.
It draws interest for glp-1 & incretin receptor agonists and is prescribed for its approved indication(s).
Yes for its approved use(s), with caveats — strong human trial evidence underpins the label, but broader wellness/longevity claims are not proven.
Uses beyond its approved indication(s); General anti-aging or longevity; Unsupervised wellness experimentation.
A clinically validated drug for its lane; outside that lane, treat broader claims with caution.
Before you decide, compare Tirzepatide with Semaglutide, Liraglutide, Retatrutide. See all →
Tirzepatide is an approved drug in the glp-1 & incretin receptor agonists.
Activating the GLP-1 receptor to enhance insulin release, slow gastric emptying, and reduce appetite.
It draws interest for glp-1 & incretin receptor agonists and is prescribed for its approved indication(s).
Yes for its approved use(s), with caveats — strong human trial evidence underpins the label, but broader wellness/longevity claims are not proven.
A dual GIP/GLP-1 receptor agonist with large randomized trials (SURMOUNT for weight, SURPASS for diabetes). FDA-approved as Mounjaro and Zepbound; program data show among the largest average weight reductions reported for a drug. Strongly evidenced, with the same GI-tolerability and continued-use caveats as other incretins.
Verified citations resolve to PubMed / FDA. See how we score.
Tirzepatide: the research file
What it is
Tirzepatide (development code LY3298176) is a synthetic, 39-amino-acid modified peptide engineered as a "twincretin" — a single molecule that activates two incretin hormone receptors at once. It carries a C20 fatty diacid side chain that binds serum albumin, extending its half-life to roughly five days and enabling once-weekly subcutaneous dosing. It is the active ingredient in Eli Lilly's FDA-approved products Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea).
How it works
Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, the first approved agent to engage both incretin pathways. Through GLP-1 receptor activation it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways; GIP receptor activation contributes additional insulinotropic effects and is thought to influence energy metabolism and adipose tissue handling. Its peptide backbone is more closely modeled on native GIP, and it is biased toward GIP-receptor engagement relative to GLP-1, though the precise contribution of the GIP arm to its clinical effect in humans remains an area of active investigation. The net clinical result is improved glycemic control and substantial reductions in body weight and food intake.
What the evidence shows
Human evidence for tirzepatide is unusually robust, anchored by the large randomized SURPASS (diabetes) and SURMOUNT (obesity) programs. In SURPASS-2 (Frias et al., NEJM 2021), tirzepatide produced greater HbA1c and body-weight reductions than injectable semaglutide in type 2 diabetes across all doses. In the placebo-controlled SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), adults with obesity or overweight lost roughly 15–21% of body weight on average depending on dose. SURMOUNT-OSA (Malhotra et al., NEJM 2024) showed reductions in apnea-hypopnea index in patients with obesity and moderate-to-severe obstructive sleep apnea, supporting the December 2024 FDA approval for that indication. A dedicated cardiovascular outcomes trial (SURPASS-CVOT) and the SUMMIT heart-failure-with-preserved-ejection-fraction program have reported results, but long-term hard-outcome data are newer and still being integrated; readers should treat cardiovascular benefit as supported but more recently established than the glycemic and weight findings.
Safety considerations
The most common adverse effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and decreased appetite — typically arising during dose escalation and often diminishing over time. The FDA label carries a boxed warning regarding thyroid C-cell tumors based on rodent studies (the human relevance is unknown), and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Documented risks include acute pancreatitis, gallbladder disease, acute kidney injury (often via dehydration from GI losses), hypersensitivity reactions, and hypoglycemia when combined with insulin or sulfonylureas. Important unknowns remain around long-term safety, effects of regained weight after discontinuation, use in pregnancy, and potential reduced effectiveness of oral medications (including oral contraceptives) due to delayed gastric emptying.
Regulatory status
Tirzepatide is FDA-approved (not investigational) — as Mounjaro for type 2 diabetes (May 2022) and as Zepbound for chronic weight management (November 2023) and moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024); it is also authorized in the EU, UK, and other jurisdictions. It is a prescription drug, and compounded or research-grade "tirzepatide" sold outside the regulated supply chain is not FDA-approved and carries quality and safety risks.
- First-in-class dual GIP/GLP-1 receptor agonist (a 39-amino-acid peptide), distinct from single-pathway GLP-1 agonists like semaglutide
- Marketed by Eli Lilly as Mounjaro (diabetes) and Zepbound (weight management and obstructive sleep apnea)
- Albumin-binding fatty-acid modification gives an ~5-day half-life, supporting once-weekly administration
- In the head-to-head SURPASS-2 trial it outperformed semaglutide on HbA1c and weight reduction in type 2 diabetes
- FDA approvals span 2022 (diabetes), 2023 (obesity), and 2024 (obstructive sleep apnea)
- Carries a boxed warning for thyroid C-cell tumors based on rodent data; human relevance is unknown
- [1]Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine, 2022, PMID 35658024
- [2]Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — New England Journal of Medicine, 2021, PMID 34170647
- [3]Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) — New England Journal of Medicine, 2024, PMID 38912654
- [4]MOUNJARO (tirzepatide) injection — FDA Prescribing Information — U.S. FDA / accessdata.fda.gov, 2022 (rev. 2025)
Currently sits at Approved use — FDA-approved for a specific indication — the strongest lane.
Jargon, decoded: · · ·
Areas this compound is studied or discussed for — not guaranteed effects.
- Tirzepatide is a dual agonist — it activates both the GIP and GLP-1 receptors, two incretin pathways, in a single molecule.
- It is FDA-approved (brands Mounjaro for type-2 diabetes, Zepbound for weight management), supported by the SURPASS and SURMOUNT trial programs.
- It has a long half-life of about five days, the basis for once-weekly approved formulations.
- Strong evidence for its approved uses; broader wellness/longevity claims are not approved or proven.
- Common effects are gastrointestinal; see the FDA label for warnings and contraindications.
Marketing claim vs what the data actually shows. Tap a row for detail.
Verdicts describe the state of the evidence, not invented study results. Open References for the underlying citations.
Stack fit
Decision clarity: HighClear evidence lane, known safety, and regulatory clarity.
Stack verdict: A clinically validated drug for its lane; outside that lane, treat broader claims with caution.
Tirzepatide is not established for:
Tier ranking
A weighted evidence score of 92/100 places tirzepatide in S tier — based on published evidence, not popularity.
Weighted evidence score 92/100
Why not A: supported by human evidence, preclinical depth, mechanism confidence, safety clarity, regulatory clarity, practical relevance.
What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.
What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.
- Tirzepatide is an FDA-approved drug for specific indications.
- It belongs to the GLP-1 & incretin receptor agonists class.
- Its principal mechanism is characterized in the literature.
- Long-term safety in healthy users, and full drug-interaction risk.
- Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
This is not medical advice. These are areas where professional guidance and better evidence matter most.
See it next to its closest alternatives.
Full brief
A deeper, chapter-by-chapter research briefing. Tap any chapter to expand.
- What it is
- The GLP-1 receptor agonism mechanism
- The approval lane
- Why Established, and not higher or lower
- Proven lane vs speculative lane
- What people report
- Regulatory status
- What changed recently
01What it is
Simple takeaway: Tirzepatide is an approved drug in the glp-1 & incretin receptor agonists.
Peptides that mimic incretin hormones to influence insulin secretion, gastric emptying, and appetite. This class includes the approved metabolic drugs and newer multi-receptor agonists. It has been through human clinical development for its approved indication(s).
02The GLP-1 receptor agonism mechanism
Simple takeaway: Activating the GLP-1 receptor to enhance insulin release, slow gastric emptying, and reduce appetite.
GLP-1 receptor agonists mimic the incretin hormone GLP-1. Activation increases glucose-dependent insulin secretion (so insulin rises mainly when glucose is high), slows the rate at which the stomach empties, and acts on central pathways that reduce appetite. This combination underpins their use in glucose control and weight management.
03The approval lane
Simple takeaway: Tirzepatide's strongest evidence is its FDA-approved use.
Approved (Mounjaro, Zepbound) for type 2 diabetes and weight management.
04Why Established, and not higher or lower
Simple takeaway: Composite maturity 4.7/5.
What holds it back: remaining gaps and limited replication. What supports its placement: human evidence, preclinical depth, mechanism confidence, safety clarity, regulatory clarity, practical relevance. Stronger human trials, clearer long-term safety data, and regulatory progress would move it up; a safety signal or failure to replicate would move it down.
05Proven lane vs speculative lane
Simple takeaway: The approved use is real; broader wellness claims are extrapolation.
What's proven is the approved indication, supported by trials. What's speculative is the longevity/wellness extrapolation that isn't on the label and hasn't been demonstrated for those uses.
06What people report
Simple takeaway: Community reports are not clinical evidence.
Online reports can surface expectation patterns and possible safety signals, but they are shaped by placebo effects, selection bias, confounders, and uncertain product quality and sourcing. We don't treat anecdotes as proof and we don't publish dosing or protocols.
07Regulatory status
Simple takeaway: FDA-approved
Approved (Mounjaro, Zepbound) for type 2 diabetes and weight management. Regulatory status can change and differs by country; several peptides are also prohibited in sport (WADA). Verify current status before relying on it.
08What changed recently
Simple takeaway: No major evidence-changing update was identified in this review window.
The current profile reflects the existing body of indexed evidence. Material changes — new trials, approvals, or safety findings — are noted here when an editor logs them.
How the community sees this vs the evidence.
Evidence tier is S. Do you agree?
Community votes reflect user perception, not scientific proof — the evidence tier comes from our Research Maturity Index. Aggregate community sentiment will appear here once enough votes are collected.
Aggregate community sentiment will appear here once enough votes are in — we don't show invented numbers.
Get notified when new studies, safety updates, regulatory changes, or the tier ranking change.
FAQs
Is Tirzepatide FDA-approved?
Yes — Tirzepatide is FDA-approved for specific medical indications. Approved (Mounjaro, Zepbound) for type 2 diabetes and weight management.
What is Tirzepatide studied for?
Tirzepatide is studied mainly for weight loss. Peptides that mimic incretin hormones to influence insulin secretion, gastric emptying, and appetite. This class includes the approved metabolic drugs and newer multi-receptor agonists.
What does the research say about Tirzepatide?
Clinically validated. Approved for medical use, with strong human evidence and characterized safety for its indications.
Is Tirzepatide safe?
It has documented safety for its approved use; off-label and long-term safety are less certain. Quality and purity from non-pharmaceutical sources is an added risk.
🧮 Reconstitution calculator (educational)
Educational reconstitution math from your own values — not medical advice or a dose recommendation. Open the full calculator →
Each unit on a 100u · 1.0 mL syringe ≈ 25 mcg of this solution.
Show the math
More water → lower concentration → more units for the same amount.
Get the vial, water, target, and 10-unit draw sent to your inbox so it's easy to reference — and follow when the evidence changes. Free, no account.
Research reference only. Not medical advice, treatment instructions, or a purchase recommendation. Consult a licensed professional.